-
公开(公告)号：US20190134180A1
公开(公告)日：2019-05-09
申请号：US16021543
申请日：2018-06-28
发明人： Kim BURGARD , Jeremy KROLL , Sarah M. LAYTON , Volker OHLINGER , Francois-Xavier ORVEILLON , Stefan PESCH , Michael Dennis PIONTKOWSKI , Michael B. ROOF , Philip UTLEY , Eric Martin VAUGHN
摘要： The present invention is related to improved modified live PRRS vaccines containing new PRRSV European strains of PRRSV and methods of use and manufacture of such vaccines.
-
42.发明申请公开(公告)号：US20180339054A1
公开(公告)日：2018-11-29
申请号：US16047313
申请日：2018-07-27
发明人： Michael AVEN , Tim LUKAS
IPC分类号： A61K47/40 , A61K47/69 , A61K9/08 , A61K31/501 , A61K9/00
摘要： A preserved liquid aqueous pharmaceutical composition includes one or more etherified cyclodextrin derivatives, at least one water-soluble preservative, and at least one pharmaceutically active compound which is poorly water-soluble, very poorly water-soluble or water-insoluble. The liquid aqueous pharmaceutical composition provides an acceptable solubility of the pharmaceutically active compound, such as pimobendan, in aqueous solution whereby the water-soluble preservatives retain their effectiveness in the presence of the etherified cyclodextrin derivatives allowing the use in an oral administration form.
-
公开(公告)号：US10029005B2
公开(公告)日：2018-07-24
申请号：US15050640
申请日：2016-02-23
IPC分类号： A61K39/00 , A61K39/145 , A61K39/12 , C12N7/00 , A61K39/42 , C07K14/005
摘要： The present invention relates to an immunogenic composition comprising: a) a modified live H3 virus of swine influenza, and b) a modified live H1 virus of swine influenza. Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by swine influenza virus in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.
-
44.发明申请公开(公告)号：US20180193317A1
公开(公告)日：2018-07-12
申请号：US15915817
申请日：2018-03-08
发明人： Marcus Stark , Ulrike D. Sent , Ingo Lang
IPC分类号： A61K31/4184 , A61K9/00 , A61K31/41 , A61K45/06 , A61K31/00
CPC分类号： A61K31/4184 , A61K9/0053 , A61K31/00 , A61K31/41 , A61K45/06 , A61K2300/00
摘要： A method is described for the treatment of systemic diseases in cats. A composition is administered to a cat, where the composition includes a therapeutically effective amount of angiotensin II receptor 1 (AT-1) antagonist (sartan).
-
45.发明申请公开(公告)号：US20180185402A1
公开(公告)日：2018-07-05
申请号：US15865339
申请日：2018-01-09
发明人： Juergen DAEMMGEN , Olaf JOENS , Rainer KLEEMANN
IPC分类号： A61K31/7048 , A61K31/341 , A61K31/44 , A61K31/4412 , A61K31/4166 , A61K31/4427 , A61K31/40 , A61K31/50 , A61K45/06 , A61K31/501 , A61K31/444
摘要： A phosphodiesterase type III (PDE III) inhibitor or Ca2+-sensitizing agent or a pharmaceutically acceptable derivative thereof is provided for the preparation of a medication for the reduction of the heart size of a patient suffering from heart failure.
-
公开(公告)号：US10010601B2
公开(公告)日：2018-07-03
申请号：US15105760
申请日：2014-12-19
发明人： Andreas Gallei , Christoph Keller , Erik Schacht , Marieke Herrel
CPC分类号： A61K39/12 , A61K2039/5254 , A61K2039/552 , C07K14/005 , C12N7/00 , C12N15/86 , C12N2770/10021 , C12N2770/10034 , C12N2770/10043 , C12Q1/02 , G01N2333/08
摘要： The present invention belongs to the field of animal health and provides means to study Porcine Reproductive and Respiratory Syndrome (PRRS), a viral disease affecting swine, and for the development of vaccines, therapeutics and diagnostics for the prophylaxis, treatment and diagnosis of PRRS. In a first consideration, the invention relates to a new PRRS virus variant, and, in a second consideration, to a nucleic acid sequence which comprises the genome of an infectious genotype I (EU) PRRS virus clone. Based on this, new PRRS vaccine candidates with improved properties are provided.
-
公开(公告)号：US20180170618A1
公开(公告)日：2018-06-21
申请号：US15841487
申请日：2017-12-14
发明人： Cristiano Tunesi
摘要： Packages that include at least one medicament therein include at least one light member affixed thereto that is capable of emitting light upon activation. The light member is activated upon the opening of the package such that, upon opening, the light member fluoresces or otherwise emits light to provide information to an end user. In some embodiments, the light generated by the light member allows the end user to locate the package in dark conditions. In other embodiments, the light generated by the light member may be configured to emit only for a time period equal to a viability time period of the medicament within the package or to change color at a time period equal to the viability time period of the medicament within the package to alert an end user that the medicament is no longer useable.
-
48.发明授权公开(公告)号：US09993544B2
公开(公告)日：2018-06-12
申请号：US15312249
申请日：2015-05-22
发明人： Gregor Meyers , Sabine Wirtz
IPC分类号： A61K39/12 , G01N33/569 , C12N7/00 , A61K39/00
CPC分类号： A61K39/12 , A61K2039/5254 , A61K2039/552 , C12N7/00 , C12N2770/24321 , C12N2770/24322 , C12N2770/24334 , C12N2770/24362 , G01N33/56983 , G01N2333/185
摘要： The present invention relates i.a. to a CSFV (classical swine fever virus) comprising a substitution of proline to lysine at amino acid position 44 of the E2 protein and a substitution of threonine to aspartic acid at amino acid position 45 of the E2 protein. Further, the present invention provides an immunogenic composition comprising the CSFV of the present invention and the use of the immunogenic composition for reducing the incidence of or severity in an animal of one or more clinical signs associated with CSF. Moreover, the present invention provides a method of differentiating animals infected with CSFV from animals vaccinated with the immunogenic composition of the present invention.
-
公开(公告)号：US20180133309A1
公开(公告)日：2018-05-17
申请号：US15801730
申请日：2017-11-02
IPC分类号： A61K39/23 , C07K14/005 , A61P31/20 , C12N7/00
CPC分类号： A61K39/23 , A61K39/12 , A61K2039/552 , A61P31/20 , C07K14/005 , C12N7/00 , C12N2750/14322 , C12N2750/14323 , C12N2750/14334 , C12N2750/14371 , C12N2770/10034
摘要： The present invention relates to a porcine parvovirus (PPV) viral protein 2 (VP2) having at amino acid position 228 a glutamic acid residue or a glutamate residue, and/or at amino acid position 414 a serine residue, and/or at amino acid position 419 a glutamine residue, and/or at amino acid position 436 a threonine residue. Further, the present invention relates to immunogenic compositions comprising said PPV viral protein 2 (VP2). Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by PPV infection in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.
-
50.发明授权公开(公告)号：US09949954B2
公开(公告)日：2018-04-24
申请号：US15411062
申请日：2017-01-20
发明人： Marcus Stark , Ulrike D. Sent , Ingo Lang
IPC分类号： A61K31/4184 , A61K31/00 , A61K31/41 , A61K45/06 , A61K9/00
CPC分类号： A61K31/4184 , A61K9/0053 , A61K31/00 , A61K31/41 , A61K45/06 , A61K2300/00
摘要： A method is described for the treatment of systemic diseases in cats. A composition is administered to a cat, where the composition includes a therapeutically effective amount of angiotensin II receptor 1 (AT-1) antagonist (sartan).
-
-
-
-
-
-
-
-
-
搜索结果
377 条记录 (耗时 0.045 秒)
